Objective: To describe the heterogeneity of electrodiagnostic (EDx) studies in Guillain-Barré syndrome (GBS) patients collected as part of the International GBS Outcome Study (IGOS). Methods: Prospectively collected clinical and EDx data were available in 957 IGOS patients from 115 centers. Only the first EDx study was included in the current analysis. Results: Median timing of the EDx study was 7 days (interquartile range 4–11) from symptom onset. Methodology varied between centers, countries and regions. Reference values from the responding 103 centers were derived locally in 49%, from publications in 37% and from a combination of these in the remaining 15%. Amplitude measurement in the EDx studies (baseline-to-peak or peak-to-peak) differed from the way this was done in the reference values, in 22% of motor and 39% of sensory conduction. There was marked variability in both motor and sensory reference values, although only a few outliers accounted for this. Conclusions: Our study showed extensive variation in the clinical practice of EDx in GBS patients among IGOS centers across the regions. Significance: Besides EDx variation in GBS patients participating in IGOS, this diversity is likely to be present in other neuromuscular disorders and centers. This underlines the need for standardization of EDx in future multinational GBS studies.

Arends, S., Drenthen, J., van den Bergh, P., Franssen, H., Hadden, R., Islam, B., et al. (2022). Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. CLINICAL NEUROPHYSIOLOGY, 138(June 2022), 231-240 [10.1016/j.clinph.2021.12.014].

Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

Balducci C.;Binda D.;Cavaletti G.;
2022

Abstract

Objective: To describe the heterogeneity of electrodiagnostic (EDx) studies in Guillain-Barré syndrome (GBS) patients collected as part of the International GBS Outcome Study (IGOS). Methods: Prospectively collected clinical and EDx data were available in 957 IGOS patients from 115 centers. Only the first EDx study was included in the current analysis. Results: Median timing of the EDx study was 7 days (interquartile range 4–11) from symptom onset. Methodology varied between centers, countries and regions. Reference values from the responding 103 centers were derived locally in 49%, from publications in 37% and from a combination of these in the remaining 15%. Amplitude measurement in the EDx studies (baseline-to-peak or peak-to-peak) differed from the way this was done in the reference values, in 22% of motor and 39% of sensory conduction. There was marked variability in both motor and sensory reference values, although only a few outliers accounted for this. Conclusions: Our study showed extensive variation in the clinical practice of EDx in GBS patients among IGOS centers across the regions. Significance: Besides EDx variation in GBS patients participating in IGOS, this diversity is likely to be present in other neuromuscular disorders and centers. This underlines the need for standardization of EDx in future multinational GBS studies.
Articolo in rivista - Articolo scientifico
AIDP; AMAN; AMSAN; Electromyography; Nerve conduction studies; Reference values;
English
231
240
10
Arends, S., Drenthen, J., van den Bergh, P., Franssen, H., Hadden, R., Islam, B., et al. (2022). Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. CLINICAL NEUROPHYSIOLOGY, 138(June 2022), 231-240 [10.1016/j.clinph.2021.12.014].
Arends, S; Drenthen, J; van den Bergh, P; Franssen, H; Hadden, R; Islam, B; Kuwabara, S; Reisin, R; Shahrizaila, N; Amino, H; Antonini, G; Attarian, S; Balducci, C; Barroso, F; Bertorini, T; Binda, D; Brannagan, T; Buermann, J; Casasnovas, C; Cavaletti, G; Chao, C; Dimachkie, M; Fulgenzi, E; Galassi, G; Gutierrez Gutierrez, G; Harbo, T; Hartung, H; Hsieh, S; Kiers, L; Lehmann, H; Manganelli, F; Marfia, G; Mataluni, G; Pardo, J; Pereon, Y; Rajabally, Y; Santoro, L; Sekiguchi, Y; Stein, B; Stettner, M; Uncini, A; Verboon, C; Verhamme, C; Vytopil, M; Waheed, W; Wang, M; Zivkovic, S; Jacobs, B; Cornblath, D
File in questo prodotto:
File Dimensione Formato  
2022 - Clin Neurophys.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 503.07 kB
Formato Adobe PDF
503.07 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/351627
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact